- Home
- NDLS vs ECOR Comparison
NDLS vs ECOR Comparison
Compare NDLS & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- ECOR
- Stock Information
- Founded
- NDLS 1995
- ECOR 2005
- Country
- NDLS United States
- ECOR United States
- Employees
- NDLS N/A
- ECOR N/A
- Industry
- NDLS Restaurants
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NDLS Consumer Discretionary
- ECOR Health Care
- Exchange
- NDLS Nasdaq
- ECOR Nasdaq
- Market Cap
- NDLS 45.2M
- ECOR 50.1M
- IPO Year
- NDLS 2013
- ECOR 2018
- Fundamental
- Price
- NDLS $0.79
- ECOR $5.22
- Analyst Decision
- NDLS Strong Buy
- ECOR Strong Buy
- Analyst Count
- NDLS 2
- ECOR 2
- Target Price
- NDLS $3.00
- ECOR $25.50
- AVG Volume (30 Days)
- NDLS 153.2K
- ECOR 84.4K
- Earning Date
- NDLS 08-06-2025
- ECOR 08-06-2025
- Dividend Yield
- NDLS N/A
- ECOR N/A
- EPS Growth
- NDLS N/A
- ECOR N/A
- EPS
- NDLS N/A
- ECOR N/A
- Revenue
- NDLS $495,670,000.00
- ECOR $26,458,000.00
- Revenue This Year
- NDLS $5.37
- ECOR $23.21
- Revenue Next Year
- NDLS $0.68
- ECOR $44.10
- P/E Ratio
- NDLS N/A
- ECOR N/A
- Revenue Growth
- NDLS N/A
- ECOR 41.54
- 52 Week Low
- NDLS $0.55
- ECOR $4.47
- 52 Week High
- NDLS $2.18
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- NDLS 44.78
- ECOR 45.50
- Support Level
- NDLS $0.76
- ECOR $5.05
- Resistance Level
- NDLS $0.82
- ECOR $5.81
- Average True Range (ATR)
- NDLS 0.06
- ECOR 0.32
- MACD
- NDLS 0.00
- ECOR 0.05
- Stochastic Oscillator
- NDLS 25.00
- ECOR 39.84
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.